Yoshiaki Usui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoshiaki Usui has a total of 205 co-authors. Here are the top co-authors by number of shared publications:
- Yukihide Momozawa
Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
31 shared publications - Hidewaki Nakagawa
RIKEN Center for Integrative Medical Sciences
26 shared publications - Koichi Matsuda
Laboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
26 shared publications - Yusuke Iwasaki
Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
24 shared publications - Hanae Iijima
Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
23 shared publications - Mikiko Endo
Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
23 shared publications
Latest Publications
- 18 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF11
Joint Effects of ALDH2 rs671 and Pathogenic Germline Variants in DNA Repair Genes on Risk of Aerodigestive and Gastrointestinal Cancers
Background: The aldehyde dehydrogenase 2 (ALDH2) rs671 (G>A) variant, common in East Asians, impairs aldehyde detoxification. Pathogenic germline variants (PGV) in homologous recombination repair (HRR) and mismatch repair (MMR) genes confer inherited susceptibility; however, their joint effects with rs671 remain poorly characterized. Methods: We conducted a case–control study of 4,418 cases of head and neck, esophageal, gastric, or colorectal cancer and 11,811 controls. Targeted sequencing identified HRR and MMR PGVs. Associations and interactions were assessed using Firth penalized logistic regression, stratified by alcohol intake. Cumulative risk was estimated using Japanese population incidence data. Results: HRR PGV carriers with the rs671 GA/AA genotype showed increased risk across all cancer sites compared with rs671 GG noncarriers. Joint effects were observed among drinkers for head and neck, esophageal, and gastric cancers and among nondrinkers for gastric and colorectal cancers. Among MMR PGV carriers, rs671 GA/AA was associated with increased risk of esophageal and colorectal cancers (odds ratio, 95.62 and 24.57, respectively), with significant interactions (P = 0.017 and 0.0011, respectively). The rs671–MMR association for esophageal cancer was evident among drinkers, whereas colorectal cancer risk was elevated in both drinkers and nondrinkers. By the age of 80 years, cumulative risk (95% confidence interval) among MMR PGV carriers with rs671 GA/AA was 35.4% (7.7–90.3) for esophageal and 87.7% (46.9–99.9) for colorectal cancer. Conclusions: Impaired aldehyde detoxification and DNA repair deficiency jointly increase site-specific cancer risk. Impact: Integrating ALDH2 rs671 genotype, DNA repair PGVs, and alcohol exposure may improve risk stratification and prevention in East Asian populations.
- 18 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF11
Joint Effects of ALDH2 rs671 and Pathogenic Germline Variants in DNA Repair Genes on Risk of Aerodigestive and Gastrointestinal Cancers
Background: The aldehyde dehydrogenase 2 (ALDH2) rs671 (G>A) variant, common in East Asians, impairs aldehyde detoxification. Pathogenic germline variants (PGV) in homologous recombination repair (HRR) and mismatch repair (MMR) genes confer inherited susceptibility; however, their joint effects with rs671 remain poorly characterized. Methods: We conducted a case–control study of 4,418 cases of head and neck, esophageal, gastric, or colorectal cancer and 11,811 controls. Targeted sequencing identified HRR and MMR PGVs. Associations and interactions were assessed using Firth penalized logistic regression, stratified by alcohol intake. Cumulative risk was estimated using Japanese population incidence data. Results: HRR PGV carriers with the rs671 GA/AA genotype showed increased risk across all cancer sites compared with rs671 GG noncarriers. Joint effects were observed among drinkers for head and neck, esophageal, and gastric cancers and among nondrinkers for gastric and colorectal cancers. Among MMR PGV carriers, rs671 GA/AA was associated with increased risk of esophageal and colorectal cancers (odds ratio, 95.62 and 24.57, respectively), with significant interactions (P = 0.017 and 0.0011, respectively). The rs671–MMR association for esophageal cancer was evident among drinkers, whereas colorectal cancer risk was elevated in both drinkers and nondrinkers. By the age of 80 years, cumulative risk (95% confidence interval) among MMR PGV carriers with rs671 GA/AA was 35.4% (7.7–90.3) for esophageal and 87.7% (46.9–99.9) for colorectal cancer. Conclusions: Impaired aldehyde detoxification and DNA repair deficiency jointly increase site-specific cancer risk. Impact: Integrating ALDH2 rs671 genotype, DNA repair PGVs, and alcohol exposure may improve risk stratification and prevention in East Asian populations.
- Open Access
- 13 November 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1)
Pan-cancer prevalence, risk, and clinical and demographic characteristics of Lynch Syndrome-associated variants in BioBank Japan
Background Although germline testing for DNA mismatch repair (MMR) genes is routinely performed, clinical guidelines highlight evidence gaps due to limited populations and biases. We examined germline pathogenic variants of MMR genes (MLH1, MSH2, MSH6, and PMS2) in 112,927 unselected individuals from BioBank Japan. Methods We analyzed 74,085 cancer patients with 23 cancer types and 38,842 controls matched by sex, age, and hospital area from BioBank Japan, collected between April 2003 and March 2018. Germline pathogenic variants in the coding regions and 2 bp flanking intronic sequences of MMR genes were identified using a multiplex PCR-based target sequencing method. We examined associations with cancer types and demographic characterization of the pathogenic variants, comparing findings to existing clinical guidelines. Results Here we show 228 pathogenic variants identified in MMR genes, with pathogenic MSH6 variants most frequently observed in endometrial cancer and 12 other significant associations. Twelve other significant associations are noted across a broad range of odds ratios, whereas pancreatic cancer exhibits no such association. Pathogenic variant carriers are diagnosed up to 12.4 years earlier than non-carriers, and colorectal and gastric cancers are diagnosed up to 16.4 years later than indicated by the guidelines. Higher carrier frequencies are observed in patients with both colorectal and endometrial cancers (24.8%) and in those with endometrial cancer and a family history of endometrial (26.0%) or colorectal (16.1%) cancers. Conclusions This study provides critical insights for clinical guidelines on the associations between cancer types, age at diagnosis, and carrier frequency.
- 13 November 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1)
Open AccessPan-cancer prevalence, risk, and clinical and demographic characteristics of Lynch Syndrome-associated variants in BioBank Japan
Background Although germline testing for DNA mismatch repair (MMR) genes is routinely performed, clinical guidelines highlight evidence gaps due to limited populations and biases. We examined germline pathogenic variants of MMR genes (MLH1, MSH2, MSH6, and PMS2) in 112,927 unselected individuals from BioBank Japan. Methods We analyzed 74,085 cancer patients with 23 cancer types and 38,842 controls matched by sex, age, and hospital area from BioBank Japan, collected between April 2003 and March 2018. Germline pathogenic variants in the coding regions and 2 bp flanking intronic sequences of MMR genes were identified using a multiplex PCR-based target sequencing method. We examined associations with cancer types and demographic characterization of the pathogenic variants, comparing findings to existing clinical guidelines. Results Here we show 228 pathogenic variants identified in MMR genes, with pathogenic MSH6 variants most frequently observed in endometrial cancer and 12 other significant associations. Twelve other significant associations are noted across a broad range of odds ratios, whereas pancreatic cancer exhibits no such association. Pathogenic variant carriers are diagnosed up to 12.4 years earlier than non-carriers, and colorectal and gastric cancers are diagnosed up to 16.4 years later than indicated by the guidelines. Higher carrier frequencies are observed in patients with both colorectal and endometrial cancers (24.8%) and in those with endometrial cancer and a family history of endometrial (26.0%) or colorectal (16.1%) cancers. Conclusions This study provides critical insights for clinical guidelines on the associations between cancer types, age at diagnosis, and carrier frequency.
- Open Access
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400945
Case-Control Study for 23 Cancer Types With Functional Analysis of CHEK2 : Risk Estimation and Clinical Recommendations in East Asia
PURPOSE: CHEK2 is the frequently detected cancer-predisposing gene in female breast cancer. In addition, the association with the risks of other cancer types has been suggested, and clinical management has also been discussed. Although clinical relevance of germline variants differs across population, there is little evidence of the clinical relevance of CHEK2 germline variants in East Asia. METHODS: Targeted sequencing and functional analyses of missense variants for the coding region of CHEK2 in 111,571 East Asian individuals were performed. Variants classified as pathogenic/likely pathogenic in ClinVar, predicted loss-of-function, or functionally impaired in functional analysis were defined as germline damaging variants (gDVs). We evaluated the association between CHEK2 gDVs and the risk of 23 cancer types. We also compared the clinical characteristics of carriers and noncarriers among patients with CHEK2 -associated cancers. RESULTS: We identified 77 gDVs including 36 functionally impaired missense variants. CHEK2 gDVs were significantly associated exclusively with prostate cancer (odds ratio [OR], 1.8 [95% CI, 1.2 to 2.6]; P = 1.7 × 10 −3 ), in addition to female breast cancer (OR, 1.8 [95% CI, 1.3 to 2.6]; P = 1.2 × 10 −3 ), among 23 cancer types. There were no differences in age at diagnosis, pathologic status, and prognosis between carriers and noncarriers. Besides, there was no association with the risk of cancer types with high incidence rates in East Asian countries. CONCLUSION: CHEK2 gDVs were associated with female breast and prostate cancer risks in East Asia. The necessity of additional systematic clinical management for all CHEK2 gDV carriers should be carefully discussed, and standard cancer screening is recommended unless no other clinical features suggestive of cancer predisposition are noted in East Asia.
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400945
Open AccessCase-Control Study for 23 Cancer Types With Functional Analysis of CHEK2 : Risk Estimation and Clinical Recommendations in East Asia
PURPOSE: CHEK2 is the frequently detected cancer-predisposing gene in female breast cancer. In addition, the association with the risks of other cancer types has been suggested, and clinical management has also been discussed. Although clinical relevance of germline variants differs across population, there is little evidence of the clinical relevance of CHEK2 germline variants in East Asia. METHODS: Targeted sequencing and functional analyses of missense variants for the coding region of CHEK2 in 111,571 East Asian individuals were performed. Variants classified as pathogenic/likely pathogenic in ClinVar, predicted loss-of-function, or functionally impaired in functional analysis were defined as germline damaging variants (gDVs). We evaluated the association between CHEK2 gDVs and the risk of 23 cancer types. We also compared the clinical characteristics of carriers and noncarriers among patients with CHEK2 -associated cancers. RESULTS: We identified 77 gDVs including 36 functionally impaired missense variants. CHEK2 gDVs were significantly associated exclusively with prostate cancer (odds ratio [OR], 1.8 [95% CI, 1.2 to 2.6]; P = 1.7 × 10 −3 ), in addition to female breast cancer (OR, 1.8 [95% CI, 1.3 to 2.6]; P = 1.2 × 10 −3 ), among 23 cancer types. There were no differences in age at diagnosis, pathologic status, and prognosis between carriers and noncarriers. Besides, there was no association with the risk of cancer types with high incidence rates in East Asian countries. CONCLUSION: CHEK2 gDVs were associated with female breast and prostate cancer risks in East Asia. The necessity of additional systematic clinical management for all CHEK2 gDV carriers should be carefully discussed, and standard cancer screening is recommended unless no other clinical features suggestive of cancer predisposition are noted in East Asia.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases
Association of TP53-CHIP with each outcome among all models
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases
Association of TP53-CHIP with each outcome among all models
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases
Bland-Altman plots for targeted sequencing and ddPCR
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases
Bland-Altman plots for targeted sequencing and ddPCR
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases
Impact of acetaldehyde and TP53-CHIP on myeloid neoplasm mortality. A, The cause-specific survival from myeloid neoplasms was estimated using the Kaplan–Meier method. Individuals prone to acetaldehyde exposure were defined as individuals with both rs671 Lys+ and ever-drinker status. B, HRs and their 95% CIs were estimated using Cox proportional hazards models of myeloid neoplasm mortality adjusted for age, sex, drinking habits, alcohol consumption, smoking habits, Brinkman index, body mass index, comorbidities (hyperlipidemia, hypertension, diabetes, and cancer), and ALDH2. AcAld, acetaldehyde.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases
Impact of acetaldehyde and TP53-CHIP on myeloid neoplasm mortality. A, The cause-specific survival from myeloid neoplasms was estimated using the Kaplan–Meier method. Individuals prone to acetaldehyde exposure were defined as individuals with both rs671 Lys+ and ever-drinker status. B, HRs and their 95% CIs were estimated using Cox proportional hazards models of myeloid neoplasm mortality adjusted for age, sex, drinking habits, alcohol consumption, smoking habits, Brinkman index, body mass index, comorbidities (hyperlipidemia, hypertension, diabetes, and cancer), and ALDH2. AcAld, acetaldehyde.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases
Mutation patterns and hotspot locations of TP53-CHIP. A, Mutation patterns of CHIP in this study (1,198 mutations) and somatic mutations in the NCI TP53 database (RRID: SCR_026878; 28,310 mutations). B, Mutations that 10 or more individuals with TP53-CHIP carry in this study are shown. The vertical axis represents the number of carriers. Detailed information of mutations is provided in Supplementary Table S2. C, Codon of the hotspot mutation, which accounted for more than 1% of all mutations, in the NCI TP53 database (RRID: SCR_026878). The vertical axis represents the proportion of mutations at each codon. Indel, insertion or deletion.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases
Mutation patterns and hotspot locations of TP53-CHIP. A, Mutation patterns of CHIP in this study (1,198 mutations) and somatic mutations in the NCI TP53 database (RRID: SCR_026878; 28,310 mutations). B, Mutations that 10 or more individuals with TP53-CHIP carry in this study are shown. The vertical axis represents the number of carriers. Detailed information of mutations is provided in Supplementary Table S2. C, Codon of the hotspot mutation, which accounted for more than 1% of all mutations, in the NCI TP53 database (RRID: SCR_026878). The vertical axis represents the proportion of mutations at each codon. Indel, insertion or deletion.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases
Causes of death for evaluation of disease-specific mortality
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases
Causes of death for evaluation of disease-specific mortality